Neonatal administration of exendin-4, an agonist of the glucagon-like peptide 1 receptor, has been previously shown to prevent hepatic oxidative stress in male offspring at 7–9 weeks of age, and in doing so mitigated hepatic insulin resistance [116]. This evidence concerns the gene GLP1R and Insulin resistance.